Home/Pipeline/REC-617

REC-617

Advanced Solid Tumors

Phase 1/2Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1/2

Status

Active

Company

Recursion Pharmaceuticals

About Recursion Pharmaceuticals

Recursion Pharmaceuticals aims to decode biology and radically improve lives by applying artificial intelligence and automation to drug discovery. Its core asset is the Recursion OS, a comprehensive platform that generates and analyzes petabytes of proprietary biological data to fuel an internal pipeline of potential first-in-class and best-in-class therapies. The company has advanced several programs into clinical trials, secured strategic partnerships with industry leaders, and is building one of the most powerful supercomputers in biopharma to scale its operations.

View full company profile

Therapeutic Areas

Oncology Rare Disease

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
SHR-1701	Jiangsu Hengrui Medicine	Phase 1	Active
BAY 1895344	Bayer	Phase 1	Active
HS-10342	Hansoh Pharma	Phase 1/2	Active
ANKTIVA® + M-ceNK	ImmunityBio	Phase 1	Active
DFTX-101	Definium Therapeutics	Phase 1/2	Active
ZW220	Zymeworks	Preclinical	Active
NX-1607	Nurix Therapeutics	Phase 1a	Active
IMA402 (TCR Bispecific)	Immatics	Phase 1	Active
IMA403 (TCR Bispecific)	Immatics	Pre-clinical	Research
BCA101	Bicara Therapeutics	Phase 1	Completed
AN4005	Adlai Nortye	Preclinical	IND-enabling
AN3025	Adlai Nortye	Preclinical	Active